Used primarily in targeted cancer therapies, this compound is designed to enhance the delivery of thalidomide derivatives to specific cells. It is particularly effective in proteolysis-targeting chimeras (PROTACs), where it helps degrade disease-causing proteins by recruiting E3 ubiquitin ligases. Its application extends to research in autoimmune diseases and inflammatory conditions, offering potential for developing treatments with reduced off-target effects. Additionally, it is explored in drug conjugates to improve therapeutic efficacy and minimize toxicity in treatments for multiple myeloma and other malignancies.